Published in J Endocrinol Invest on December 04, 2009
Acromegaly: the disease, its impact on patients, and managing the burden of long-term treatment. Int J Gen Med (2013) 0.99
Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly. Pituitary (2016) 0.84
Medical therapy of acromegaly. Int J Endocrinol (2012) 0.82
Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline. J Endocrinol Invest (2014) 0.76
Predictors of Quality of Life in Acromegaly: No Consensus on Biochemical Parameters. Front Endocrinol (Lausanne) (2017) 0.75
Remarkable Shrinkage of a Growth Hormone (GH)-secreting Macroadenoma Induced by Somatostatin Analogue Administration: A Case Report and Literature Review. Intern Med (2017) 0.75
Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. Lancet (2001) 4.80
Guidelines for acromegaly management: an update. J Clin Endocrinol Metab (2009) 2.96
Prevalence and predictive factors for regional osteopenia in women with anorexia nervosa. Ann Intern Med (2000) 2.80
Eating disorders. N Engl J Med (1999) 2.77
Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab (2008) 2.70
A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab (2010) 2.33
Inhaled human insulin treatment in patients with type 2 diabetes mellitus. Ann Intern Med (2001) 2.32
Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab (1996) 2.30
Determinants of increased energy expenditure in HIV-infected women. Am J Clin Nutr (1998) 2.21
Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation. J Clin Endocrinol Metab (2011) 2.16
Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med (2000) 2.16
Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J Clin Endocrinol Metab (2010) 2.16
Impairment of GH secretion in adults with primary empty sella. J Endocrinol Invest (2002) 2.09
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet (2001) 2.08
Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how? Osteoporos Int (2013) 2.00
Androgen deficiency in women with hypopituitarism. J Clin Endocrinol Metab (2001) 1.95
Changes in regional fat redistribution and the effects of estrogen during spontaneous weight gain in women with anorexia nervosa. Am J Clin Nutr (2001) 1.91
Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab (1998) 1.91
The effects of anorexia nervosa on bone metabolism in female adolescents. J Clin Endocrinol Metab (1999) 1.89
A longitudinal evaluation of bone mineral density in adult men with histories of delayed puberty. J Clin Endocrinol Metab (1996) 1.85
Effects of testosterone and progressive resistance training in eugonadal men with AIDS wasting. A randomized, controlled trial. Ann Intern Med (2000) 1.74
The influence of gonadal hormones on conditioned fear extinction in healthy humans. Neuroscience (2010) 1.69
Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab (1998) 1.68
Treatment satisfaction with inhaled insulin in patients with type 1 diabetes: a randomized controlled trial. Diabetes Care (2001) 1.68
Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab (2008) 1.66
Mechanisms of osteoporosis in adult and adolescent women with anorexia nervosa. J Clin Endocrinol Metab (1989) 1.61
Prevalence and early diagnosis of coeliac disease in autoimmune thyroid disorders. Ital J Gastroenterol Hepatol (1999) 1.60
Osteopenia in men with a history of delayed puberty. N Engl J Med (1992) 1.59
Biochemical assessment of Cushing's disease in patients with corticotroph macroadenomas. J Clin Endocrinol Metab (1998) 1.57
Noninvasive evaluation of cardiac function in hypothyroidism. Response to gradual thyroxine replacement. N Engl J Med (1977) 1.55
Effects of short-term recombinant human insulin-like growth factor I administration on bone turnover in osteopenic women with anorexia nervosa. J Clin Endocrinol Metab (1996) 1.54
Decreased bone density in hyperprolactinemic women. N Engl J Med (1980) 1.53
Assessment of macronutrient and micronutrient intake in women with anorexia nervosa. Int J Eat Disord (2000) 1.49
Body fat distribution measured with CT: correlations in healthy subjects, patients with anorexia nervosa, and patients with Cushing syndrome. Radiology (1989) 1.46
Predictive value of pentagastrin test for preoperative differential diagnosis between C-cell hyperplasia and medullary thyroid carcinoma in patients with moderately elevated basal calcitonin levels. Clin Endocrinol (Oxf) (2009) 1.46
Spinal deformity index in patients with type 2 diabetes. Endocrine (2012) 1.45
Macimorelin (AEZS-130)-stimulated growth hormone (GH) test: validation of a novel oral stimulation test for the diagnosis of adult GH deficiency. J Clin Endocrinol Metab (2013) 1.45
Growth hormone and heart performance. A novel mechanism of cardiac wall stress regulation in humans. Eur Heart J (1997) 1.43
The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Clin Endocrinol (Oxf) (2000) 1.40
CV 205-502 treatment in therapy-resistant acromegalic patients. Eur J Endocrinol (1995) 1.40
[Effectiveness of and tolerability to oral desmopressin in the treatment of central diabetes insipidus]. Minerva Med (1992) 1.39
ACROSTUDY: the Italian experience. Endocrine (2014) 1.38
Calcium antagonists and hormone release. I. Effects of verapamil on insulin release in normal subjects and patients with islet-cell tumor. Metabolism (1980) 1.38
Body composition and endocrine function in women with acquired immunodeficiency syndrome wasting. J Clin Endocrinol Metab (1997) 1.36
Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. N Engl J Med (1994) 1.36
Endoscopic endonasal transsphenoidal approach: outcome analysis of 100 consecutive procedures. Minim Invasive Neurosurg (2002) 1.35
Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized, placebo-controlled trial. Ann Intern Med (1996) 1.34
Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea. J Clin Endocrinol Metab (1992) 1.34
Osteoporosis in men with hyperprolactinemic hypogonadism. Ann Intern Med (1986) 1.34
Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Ann Intern Med (2000) 1.33
Truncal adiposity, relative growth hormone deficiency, and cardiovascular risk. J Clin Endocrinol Metab (2004) 1.31
Severity of osteopenia in estrogen-deficient women with anorexia nervosa and hypothalamic amenorrhea. J Clin Endocrinol Metab (1999) 1.31
Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34): a randomized controlled trial. JAMA (1998) 1.30
Effects of testosterone replacement in androgen-deficient women with hypopituitarism: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab (2006) 1.27
Clinically nonfunctioning pituitary tumors are monoclonal in origin. J Clin Invest (1990) 1.27
A consensus on the diagnosis and treatment of acromegaly complications. Pituitary (2013) 1.26
Effects of fasting and glucose infusion on basal and overnight leptin concentrations in normal-weight women. Am J Clin Nutr (1997) 1.26
Serum leptin levels in women with anorexia nervosa. J Clin Endocrinol Metab (1996) 1.26
Spectrum of pituitary alterations with mild and severe thyroid impairment. J Clin Endocrinol Metab (1978) 1.24
Osteoporosis in men with idiopathic hypogonadotropic hypogonadism. Ann Intern Med (1987) 1.23
Primary empty sella: Why and when to investigate hypothalamic-pituitary function. J Endocrinol Invest (2010) 1.21
Inflammatory cardiovascular risk markers in women with hypopituitarism. J Clin Endocrinol Metab (2001) 1.20
Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab (1989) 1.18
Primary medical therapy of micro- and macroprolactinomas in men. J Clin Endocrinol Metab (2000) 1.17
Clinical characterization of familial isolated pituitary adenomas. J Clin Endocrinol Metab (2006) 1.17
A novel programme to evaluate and communicate 10-year risk of CHD reduces predicted risk and improves patients' modifiable risk factor profile. Int J Clin Pract (2008) 1.16
Prevalence of hypogonadism among men with weight loss related to human immunodeficiency virus infection who were receiving highly active antiretroviral therapy. Clin Infect Dis (2000) 1.16
The effect of glucocorticoid administration on human pituitary secretion of thyrotropin and prolactin. J Clin Endocrinol Metab (1976) 1.15
Loss of lean body and muscle mass correlates with androgen levels in hypogonadal men with acquired immunodeficiency syndrome and wasting. J Clin Endocrinol Metab (1996) 1.15
Evaluation of health-related quality of life in patients with Cushing's syndrome with a new questionnaire. Eur J Endocrinol (2008) 1.14
Diagnostic and prognostic implications of the World Health Organization classification of neuroendocrine tumors. J Endocrinol Invest (2008) 1.14
Quantitative assessment of cross-sectional muscle area, functional status, and muscle strength in men with the acquired immunodeficiency syndrome wasting syndrome. J Clin Endocrinol Metab (1999) 1.14
Development and factor analysis of a questionnaire to measure patient satisfaction with injected and inhaled insulin for type 1 diabetes. Diabetes Care (2000) 1.13
Cloning of cDNA encoding the pre-beta subunit of mouse thyrotropin. Proc Natl Acad Sci U S A (1983) 1.11
Pituitary secretion of free alpha and beta subunit of human thyrotropin in patients with thyroid disorders. J Clin Endocrinol Metab (1975) 1.10
Structured exercise training programme versus hypocaloric hyperproteic diet in obese polycystic ovary syndrome patients with anovulatory infertility: a 24-week pilot study. Hum Reprod (2007) 1.10
Current management practices for acromegaly: an international survey. Pituitary (2011) 1.10
Preservation of neuroendocrine control of reproductive function despite severe undernutrition. J Clin Endocrinol Metab (2004) 1.09
Calcium antagonists and hormone release. II. Effects of verapamil on basal, gonadotropin-releasing hormone- and thyrotropin-releasing hormone-induced pituitary hormone release in normal subjects. J Clin Endocrinol Metab (1980) 1.09
Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab (1996) 1.09
Clinical review 45: Clinically nonfunctioning pituitary adenomas. J Clin Endocrinol Metab (1993) 1.09
Reduction of plasma immunoreactive somatomedin C during fasting in humans. J Clin Endocrinol Metab (1981) 1.08
Abnormal cortisol secretion and responses to corticotropin-releasing hormone in women with hypothalamic amenorrhea. J Clin Endocrinol Metab (1990) 1.07
Octreotide treatment of acromegaly. A randomized, multicenter study. Ann Intern Med (1992) 1.07
Cardiac structural and functional abnormalities in adult patients with growth hormone deficiency. J Clin Endocrinol Metab (1993) 1.07
Long-term mortality after transsphenoidal surgery for Cushing disease. Ann Intern Med (1999) 1.06
Thyrotropin-induced hyperthyroidism: use of alpha and beta subunit levels to identify patients with pituitary tumors. J Clin Endocrinol Metab (1977) 1.05
Increase in bone mass after treatment of hyperprolactinemic amenorrhea. N Engl J Med (1986) 1.05
Secretion of alpha subunit of glycoprotein hormones by pituitary adenomas. J Clin Endocrinol Metab (1976) 1.05
Decreased leptin levels in normal weight women with hypothalamic amenorrhea: the effects of body composition and nutritional intake. J Clin Endocrinol Metab (1998) 1.03
Androgens in women with anorexia nervosa and normal-weight women with hypothalamic amenorrhea. J Clin Endocrinol Metab (2007) 1.03
Clinical review 117: Hormonal determinants and disorders of peak bone mass in children. J Clin Endocrinol Metab (2000) 1.03